Optinose Announces Preliminary Unaudited Fourth Quarter 2024 XHANCE Net Revenue of $22.4 Million
Portfolio Pulse from
Optinose reported preliminary unaudited net revenue of $22.4 million for Q4 2024, with an estimated 20% growth in XHANCE prescriptions from Q3 to Q4 2024.
January 15, 2025 | 12:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Optinose announced preliminary unaudited net revenue of $22.4 million for Q4 2024, with a 20% growth in XHANCE prescriptions from Q3 to Q4 2024.
The 20% growth in XHANCE prescriptions and the reported $22.4 million in net revenue for Q4 2024 indicate strong performance and potential positive impact on Optinose's stock price. This growth suggests increased market acceptance and potential for future revenue increases.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100